Effect of screening for type 2 diabetes on healthcare costs: a register-based study among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009

Diabetologia

Volumn 61, Issue 6, 2018, Pages 1306-1314

  Sortsø, Camilla ^a   Komkova, Anastasija ^a   Sandbæk, Annelli ^b   Griffin, Simon J ^b,c   Emneus, Martha ^a   Lauritzen, Torsten ^b   Simmons, Rebecca K ^b,d,e,f  

^a Institute of Applied Economics and Health Research   (Denmark)

^b Section of General Practice   (Denmark)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e Aarhus Institute of Advanced Studies   (Denmark)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

ADDITION study; Diabetes; Healthcare costs; Screening

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; DENMARK; FEMALE; GENERAL PRACTICE; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH SERVICE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; CONTROLLED CLINICAL TRIAL; ECONOMICS; GLUCOSE BLOOD LEVEL; MASS SCREENING; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; TIME FACTOR;

ADULT; AGED; BLOOD GLUCOSE; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS;

EID: 85044031777     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-018-4594-2     Document Type: Article

References (30)

1. Kahn R, Alperin P, Eddy D et al (2010) Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375:1365–1374
2. Schuetz CA, Alperin P, Guda S et al (2013) A standardized vascular disease health check in europe: a cost-effectiveness analysis. PLoS One 8:e66454
3. Herman WH, Ye W, Griffin SJ et al (2015) Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION-Europe). Diabetes Care 38:1449–1455
4. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ et al (2012) Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 380:1741–1748
5. Simmons RK, Griffin SJ, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbaek A (2017) Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults. Diabetologia 60:2183–2191
6. Simmons RK, Griffin SJ, Lauritzen T, Sandbaek A (2017) Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia 60:2192–2199
7. Lauritzen T, Griffin S, Borch-Johnsen K et al (2000) The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord J Int Assoc Study Obes 24(Suppl 3):S6–S11
8. Christensen JO, Sandbaek A, Lauritzen T, Borch-Johnsen K (2004) Population-based stepwise screening for unrecognised type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia 47:1566–1573
9. Griffin SJ, Borch-Johnsen K, Davies MJ et al (2011) Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 378:156–167
10. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K (2004) A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 27:727–733
11. Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003
12. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med J Br Diabet Assoc 15:539–553
13. Carstensen B, Kristensen J, Ottosen P, Borch-Johnsen K (2008) The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 51:2187–2196
14. Green A, Sortso C, Jensen PB, Emneus M (2015) Validation of the Danish National Diabetes Register. Clin Epidemiol 7:5–15
15. UNESCO (1997) International Standard Classification of Education 1997. United National Educational, Scientific and Cultural Organization, Paris
16. Thygesen LC, Daasnes C, Thaulow I, Hansen HB (2011) Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation and archiving. Scand J Public Health 39(Suppl 7):12–16
17. Dalsgaard EM, Christensen JO, Skriver MV, Borch-Johnsen K, Lauritzen T, Sandbaek A (2010) Comparison of different stepwise screening strategies for type 2 diabetes: finding from Danish general practice, ADDITION-DK. Prim Care Diabetes 4:223–229
18. Drummond M, Sculper M, Torrance G, O’Brien B, Stoddart G (2005) Methods for the economic evaluation of health care programmes. Oxford University Press, New York
19. Ettaro L, Songer TJ, Zhang P, Engelgau MM (2004) Cost-of-illness studies in diabetes mellitus. PharmacoEconomics 22:149–164
20. Bech M, Gyrd-Hansen D (2005) Effects coding in discrete choice experiments. Health Econ 14:1079–1083
21. Sortsø C, Green A, Jensen P, Emneus M (2015) Societal costs of diabetes mellitus in Denmark. Diabet Med 33:877–885
22. Gillies CL, Lambert PC, Abrams KR et al (2008) Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 336:1180–1185
23. American Diabetes Association (2013) Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36:1033–1046
24. Zhong Y, Lin PJ, Cohen JT, Winn AN, Neumann PJ (2015) Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence. Value Health 18:308–314
25. van Giessen A, Boonman-de Winter LJ, Rutten FH et al (2016) Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes. Cardiovasc Diabetol 15:48
26. Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C (2016) Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis. Dig Dis Sci 61:2108–2117
27. Neidell M, Lamster IB, Shearer B (2017) Cost-effectiveness of diabetes screening initiated through a dental visit. Community Dent Oral Epidemiol 45:275–280
28. Ministeriet-sundhedogforebyggelse (2012) DRG-leksikon. Available from http://www.sum.dk/Sundhed/DRG-systemet/DRG-leksikon.aspx. Accessed 30 April 2012
29. Pedersen KM (2010) [DRG again again]. Ugeskr Laeger 172:2205 [article in Danish]
30. Kristensen T, Rose Olsen K, Sortsø C, Ejersted C, Thomsen JL, Halling A (2013) Resources allocation and health care needs in diabetes care in Danish GP clinics. Health Policy 113:206–215